Partial
Partially Aligned
Patient Risk:
Low
Summary
Only a subset of claims are supported by the provided FDA label excerpts (notably CGRP receptor antagonism and general migraine treatment/indication). Multiple non-label statements (e.g., CDMO/manufacturer/commercialization details and patent tracking assertions) are not supported or verifiable from the supplied label sections.
Category Scores
Accurate Statements
Rimegepant sulfate is a medication used to treat migraines.
Supported by label section 1 INDICATIONS AND USAGE (as cited in provided evaluation context).
Rimegepant is a CGRP receptor antagonist.
Supported by 12.1 Mechanism of Action: "Rimegepant is a calcitonin gene-related peptide receptor antagonist."
Rimegepant works by blocking the activity of calcitonin gene-related peptide (CGRP).
Partially/implicitly supported by 12.1 Mechanism of Action describing antagonist activity (provided evaluation indicates partial support).
Unsupported Statements
Piramal Pharma Solutions serves as a contract development and manufacturing organization (CDMO) for rimegepant sulfate.
Not supported or verifiable from the provided FDA label sections.
Piramal Pharma Solutions assists in the manufacturing process of rimegepant sulfate.
Not supported or verifiable from the provided FDA label sections.
Rimegepant sulfate is marketed by Biohaven Pharmaceuticals under the brand name Nurtec ODT.
Not supported or verifiable from the provided FDA label sections.
Biohaven Pharmaceuticals is responsible for commercialization and distribution of rimegepant sulfate.
Not supported or verifiable from the provided FDA label sections.
CGRP is involved in migraine pain.
Not supported or verifiable from the provided FDA label sections.
Triptans constrict blood vessels.
Not supported or verifiable from the provided FDA label sections.
DrugPatentWatch.com provides detailed patent information, including expiration timelines, for various pharmaceuticals.
Patent database/website description is not supported by FDA label sections provided.
Information regarding the specific patent expiry dates for rimegepant sulfate is available through specialized patent tracking services.
Patent-expiry tracking is not supported by the provided FDA label sections.
Patent expiry dates are crucial for understanding when generic versions of the drug might become available.
General market/access commentary is not supported by the provided FDA label sections.
Contradictions
Important Omissions
No evaluation of dosage and administration, contraindications, boxed warnings, warnings/precautions, drug interactions, monitoring, storage, or adverse reactions is possible from the provided label excerpts because those sections were not included in the available label text.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The supported claims relate to labeled indication and mechanism. Unsupported claims are largely about manufacturing/commercialization and patent tracking; these do not directly introduce labeled dosing/safety instructions, but they reduce regulatory alignment.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Several factual assertions are not verifiable from the provided FDA label excerpts, including brand/manufacturer commercialization and patent-tracking statements.
Suggested Improvement
Restrict claims to information directly supported by the FDA label sections provided (e.g., indication and mechanism of action) and remove/avoid assertions about CDMO/manufacturer responsibilities and patent-expiry availability unless they are explicitly present in the label.